Dongsung Pharmaceutical Co.,Ltd announced that it expects to receive KRW 24 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm and other investors.
April 08, 2018
Share
Dongsung Pharmaceutical Co.,Ltd (KOSE:A002210) announced a private placement of Weapon Myeong-sik coupon unsecured 31st round unregistered coupon unguaranteed private convertible bonds for gross proceeds of KRW 24,000,000,000 on April 9, 2018. The transaction included participation from Lindh the distant Asia global pioneer Private placement the investments partnership corporation for KRW 5,000,000,000, NH Investment & Securities Co., Ltd., Investment Arm for KRW 1,000,000,000, Individual investor Lee Sang-jin for KRW 1,000,000,000 and other investors. The bonds are issued at zero coupon and will mature on April 16, 2023. The bonds can be 100% converted into 1,091,951 common shares for 4.2% stake of the company at a fixed conversion price of KRW 21,797 per share. The conversion period is from April 16, 2019 to March 16, 2023. The transaction is expected to close by April 16, 2018. The transaction has been approved by the board of directors of the company.
Dongsung Pharmaceutical Co., Ltd. is a Korea-based company engaged in the manufacture of pharmaceuticals. The Companyâs products include anti-rheumatic, anti-inflammatory analgesics, anti-inflammatory enzymes, drugs for cardiovascular system, gastrointestinal drugs, antispasmodic agents, respiratory agents, anti-histamine, dermatologicals, antibiotics, antidiarrheals, antifungals, oral hypoglycemic agents, hormones, hypnotics and others. It also produces hair dyes and cosmetics. The Company distributes its products within domestic market and to overseas markets.
Dongsung Pharmaceutical Co.,Ltd announced that it expects to receive KRW 24 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm and other investors.
DONG SUNG BIO PHARM.CO.,LTD. 
